EGFR and esophageal squamous cell carcinoma: A phase II clinical trial conducted by Luo et al. [108] showed that icotinib combined with concurrent RT was well tolerated in elderly ESCC patients compared to RT alone, with significantly prolonged 2-year OS and PFS, and patients with EGFR overexpression benefited more from icotinib in combination with RT.